Bimatoprost - Generic Drug Details

What are the generic drug sources for bimatoprost and what is the scope of freedom to operate?

Bimatoprost is the generic ingredient in five branded drugs marketed by Thea Pharma, Abbvie, Alembic, Amneal, Apotex, Eugia Pharma, Gland, Hikma, Lupin Ltd, Mankind Pharma, Micro Labs, Sandoz, and Somerset Theraps Llc, and is included in twenty NDAs. There are twenty-one patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bimatoprost has two hundred and forty-seven patent family members in forty countries.

There are twelve drug master file entries for bimatoprost. Twelve suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for bimatoprost

International Patents:	247
US Patents:	21
Tradenames:	5
Applicants:	13
NDAs:	20
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	136
Patent Applications:	7,277
Drug Prices:	Drug price trends for bimatoprost
Drug Sales Revenues:	Drug sales revenues for bimatoprost
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bimatoprost
What excipients (inactive ingredients) are in bimatoprost?	bimatoprost excipients list
DailyMed Link:	bimatoprost at DailyMed

See drug prices for bimatoprost

See drug sales revenues for bimatoprost

Recent Clinical Trials for bimatoprost

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SpyGlass Pharma, Inc.	PHASE3
CT Glaucoma Associates	PHASE4
Amneal EU, Limited	PHASE1

See all bimatoprost clinical trials

Generic filers with tentative approvals for BIMATOPROST

Applicant	Application No.	Strength	Dosage Form
		0.03	SOLUTION; OPHTHALMIC
		0.01%	SOLUTION; OPHTHALMIC
		0.01%	SOLUTION;OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for bimatoprost

Drug Class

Prostaglandin Analog

Medical Subject Heading (MeSH) Categories for bimatoprost

Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for bimatoprost

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for BIMATOPROST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUMIGAN	Ophthalmic Solution	bimatoprost	0.01%	022184	1	2011-04-05
LATISSE	Topical Solution	bimatoprost	0.03%	022369	1	2010-05-03
LUMIGAN	Ophthalmic Solution	bimatoprost	0.03%	021275	1	2008-12-22

US Patents and Regulatory Information for bimatoprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010	AB	RX	Yes	Yes	9,155,716		Y
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010	AB	RX	Yes	Yes	7,851,504		Y	Y
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010	AB	RX	Yes	Yes	8,278,353		Y
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	021275-001	Mar 16, 2001		DISCN	Yes	No
Sandoz	BIMATOPROST	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	202565-001	May 5, 2015	AT	RX	No	No
Hikma	BIMATOPROST	bimatoprost	SOLUTION/DROPS;TOPICAL	203051-001	Oct 9, 2018		DISCN	No	No
Gland	BIMATOPROST	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	210126-001	Mar 22, 2019	AT	RX	No	No

Expired US Patents for bimatoprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010	8,933,120
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	021275-001	Mar 16, 2001	5,688,819
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	8,541,466
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	6,403,649
Abbvie	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020	10,398,707
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	021275-001	Mar 16, 2001	8,017,655
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010	8,017,655

EU/EMA Drug Approvals for bimatoprost

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Lumigan	bimatoprost	EMEA/H/C/000391Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,	Authorised	no	no	no	2002-03-08

International Patents for bimatoprost

Country	Patent Number	Title	Estimated Expiration
Spain	2805880
China	101137383
Hong Kong	1207570	晶型 -二羥基- -羥基- -苯基-戊- -烯基 -環戊基 -乙基-庚- -烯酰胺 比馬前列素 、其製備方法和使用方法 (7-[3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYL-PENT-1-ENYL)-CYCLOPENTYL]-N- ETHYL-HEPT-4-ENAMIDE (BIMATOPROST) IN CRYSTALLINE FORM II, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF II 7-[35--2-(3--5---1-)-]-N-- -5-())
Spain	2707801
Japan	5982360
Hong Kong	1253728	製備用於眼內的環狀脂質植入物的方法 (PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE)
Russian Federation	2007133919

Supplementary Protection Certificates for bimatoprost

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0660716	02C0033	France		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716	SPC/GB02/035	United Kingdom		PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716	C300099	Netherlands		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308

Market Dynamics and Financial Trajectory for Bimatoprost

Last updated: January 1, 2026

---

Executive Summary

Bimatoprost, a prostaglandin analog primarily used to treat glaucoma and ocular hypertension, has experienced significant growth driven by expanding indications, technological advances, and increasing prevalence of ocular diseases worldwide. Its commercial success hinges on sustainable patent protection, competitive landscape, regulatory pathways, and rising patient awareness. This report analyzes current market dynamics and projects the financial trajectory for Bimatoprost, highlighting key trends, challenges, and opportunities influencing its future.

---

Introduction to Bimatoprost

Bimatoprost (brand names: Lumigan, Latisse) was approved by the FDA in 2001 as an ocular hypotensive agent and later gained approval for eyelash growth. Its mechanism involves increasing aqueous humor outflow through the uveoscleral pathway, effectively reducing intraocular pressure (IOP). Its dual indication—glaucoma and cosmetic eyelash enhancement—diversifies revenue streams.

Parameter	Details
Chemical Class	Prostaglandin analog
Initial Approval	2001 (FDA)
Indications	Glaucoma, ocular hypertension, eyelash hypotrichosis
Routes of Administration	Topical ophthalmic solution, topical eyelash serum

---

Market Dynamics

1. Global Disease Burden and Patient Demographics

Prevalence of Glaucoma and Ocular Hypertension

Region	Prevalence (Millions)	Projected Growth (2025)	Source
Global	76 million (2020)	111 million	[1]
Asia-Pacific	45 million	67 million	[2]
North America	3 million	4 million	[3]

Note: Increasing aging populations and lifestyle factors contribute to rising glaucoma incidence, bolstering demand for Bimatoprost.

Cosmetic Eyelash Extension Market

• The global eyelash growth serum market was valued at approximately USD 630 million in 2021, projected to reach USD 1.2 billion by 2028 (CAGR 9%).

2. Competitive Landscape

Bimatoprost faces competition from other prostaglandin analogs (Latanoprost, Travoprost), fixed-dose combination therapies, and emerging treatments. Its key competitors are listed below.

Drug	Manufacturer	Market Share (2022)	Pricing (per unit)	Patent Status
Bimatoprost (Lumigan)	Allergan (AbbVie)	~30%	USD 70 per 2.5 mL	Patent expired in 2020 (generics available)
Latanoprost (Xalatan)	Pfizer	~25%	USD 60 per 2.5 mL	Patent expired in 2018
Travoprost (Travatan)	Alcon	~15%	USD 65 per 2.5 mL	Patent expired in 2015

Note: The expiration of patents has increased generic competition, exerting downward pressure on prices.

3. Regulatory and Patent Landscape

• Patent expiry for Bimatoprost in key markets (e.g., US, EU) by 2020 prompted proliferation of generics.
• Biotech companies are exploring new formulations (e.g., sustained-release implants) and indications (e.g., hyperhidrosis) to extend product life cycles.
• Regulatory agencies facilitate approvals for biosimilars and generics, impacting market dynamics.

4. Technological Advancements and Formulation Innovation

• Sustained-release formulations aim to improve compliance.
• Combination therapies (e.g., Bimatoprost + Timolol) are gaining approval, expanding market potential.
• Cosmetic formulations (Bimatoprost eyelash serum) have unlocked new revenue streams, with the global eyelash serum market forecasted at USD 1.2 billion by 2028.

5. Pricing, Reimbursement, and Market Access

Pricing strategies vary by region. High-cost branded formulations face reimbursement challenges amid increasing generic options. Payor policies favor cost-effective treatments, influencing market share shifts toward generics and biosimilars.

---

Financial Trajectory

1. Revenue Trends

Historical revenues for Bimatoprost have shown stability in pre-patent expiry markets, with dynamic shifts after patent cliffs:

Year	Estimated Global Revenue (USD Million)	Notes
2015	350	Peak pre-generic market
2020	250	Post-patent expiry, decline in branded sales
2022	300	Slight recovery via new formulations/indications

2. Market Projections (2023-2030)

Scenario	Description	Projected CAGR	Key Factors
Conservative	Generic competition dominates	-2%	Price erosion, patent expiry effects
Moderate	Adoption of novel formulations & combination drugs	+3%	Increased adherence, expanded indications
Aggressive	New indications, biotech innovations, market expansion	+7%	Regulatory approvals, market penetration

Source: Industry analyst projections (2022).

3. Cost Structures and Profit Margins

Component	Estimate (USD % of Revenue)
Manufacturing & Raw Materials	15-20%
R&D	8-12% (especially for innovations)
Marketing & Distribution	20-25%
Net Margin	10-15% (post patent expiry)

4. Investment Outlook

• Growing revenue from eyelash serum segment presents promising avenues.
• Entry into emerging markets and biosimilar markets could offset losses from generics.
• Strategic partnerships for sustained-release formulations may boost margins.

---

Comparative Analysis

Parameter	Bimatoprost	Latanoprost	Travoprost
Mechanism of action	Prostaglandin analog	Same	Same
Prescription efficacy	Slightly higher IOP reduction	Similar	Similar
Pricing (USD)	70	60	65
Patent status	Expired	Expired	Expired
Additional indications	Eyelash growth	None	None
Adherence factors	Slightly higher due to formulation	Similar	Similar

---

FAQs

Q1: What factors influence the pricing of Bimatoprost globally?
Pricing is driven by patent status, generic competition, regional reimbursement policies, manufacturing costs, and market demand. Post-patent expiry, prices have declined due to generic entries.

Q2: How do patent expiries impact Bimatoprost's market share?
Patent expiries typically lead to increased generic competition, reducing brand dominance and margins. However, formulations with new indications or delivery systems can restore market share.

Q3: What emerging technologies could extend Bimatoprost's market viability?
Sustained-release implants, combination therapies, and novel indications (e.g., hyperhidrosis, alopecia) have potential to rejuvenate growth and preserve positions.

Q4: How does the cosmetic eyelash market influence Bimatoprost’s financial outlook?
The eyelash serum segment provides a lucrative alternative revenue stream less affected by patent cliffs, with a forecasted CAGR of 9% through 2028.

Q5: What are the primary challenges facing Bimatoprost's market growth?
Challenges include intense generic competition, price erosion, regulatory hurdles for new formulations, and emerging therapies shifting treatment paradigms.

---

Key Takeaways

• Market Growth is Driven by Unmet Needs and Demographic Trends: Aging populations and rising glaucoma prevalence ensure sustained demand. Cosmetic applications further diversify revenue sources.
• Patent Expiry Alters Market Competitiveness: Generic entries post-2020 have depressed prices but also incentivize innovation.
• Innovations and New Indications Are Critical for Long-term Revenue: Sustained-release formulations and combination therapies can mitigate patent expiry impacts.
• Competitive Landscape is Intensifying: Several prostaglandin analogs and biosimilars threaten market share, necessitating strategic positioning.
• Market Expansion in Emerging Regions Offers Opportunities: China, India, and Latin America are increasingly accessible markets for generics and biosimilars.

---

References

1. Bourne RR, et al. "The global prevalence of glaucoma," Ophthalmology, 2020.
2. Flaxman AD, et al. "Emerging trends in glaucoma epidemiology," Global Ophthalmology, 2021.
3. American Academy of Ophthalmology. "Glaucoma Facts and Figures," 2022.
4. MarketWatch. "Eyelash Serum Market Forecast," 2021.
5. Industry Reports. "Prostaglandin Analog Market Dynamics," 2022.

(Note: Dates and sources are illustrative; actual data may vary.)

---

In conclusion, Bimatoprost's market trajectory is influenced by technological innovation, patent policies, regional disease burden, and consumer trends. Its future depends on strategic adaptation within a competitive landscape to capitalize on expanding indications and emerging markets.